Ascendis Pharma A/S Ordinary Share (ASND) Stock Price

ASNDStock

$247.91+27.85%52W

Market Cap$16.26B

P/E—

PEG Ratio—

Div yield—

Beta0.33

ASND Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-6.43%

Price vs S&P 500 (4W)0.29%

VGM Score60.05

P/CF (Annual)246.67x

Book Value / Share (Quarterly)$25.17

P/TBV (Annual)22.49x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)141.43%

Cash Flow / Share (Quarterly)$5.87

Price vs S&P 500 (YTD)3.44%

Gross Margin (TTM)91.30%

Net Profit Margin (TTM)70.84%

EPS (TTM)$12.79

10-Day Avg Trading Volume0.39M

EPS Excl Extra (TTM)$12.79

Revenue Growth (5Y)152.98%

EPS (Annual)$-4.36

ROI (Annual)-75.57%

Gross Margin (Annual)86.82%

Net Profit Margin (5Y Avg)-1277.24%

Cash / Share (Quarterly)$14.23

P/E Basic Excl Extra (TTM)17.92x

Revenue Growth QoQ (YoY)114.68%

ROA (Last FY)-17.51%

Revenue Growth TTM (YoY)113.35%

EBITD / Share (TTM)$5.13

ROE (5Y Avg)-79.56%

Operating Margin (TTM)25.42%

Cash Flow / Share (Annual)$0.85

P/B Ratio9.26x

P/B Ratio (Quarterly)10.61x

Net Income / Employee (Annual)$-222,430

EV / Revenue (TTM)12.35x

Net Interest Coverage (TTM)-1.78x

ROA (TTM)43.98%

EV / EBITDA (TTM)45.02x

EPS Incl Extra (Annual)$-4.36

Current Ratio (Annual)1.04x

Quick Ratio (Quarterly)2.23x

3-Month Avg Trading Volume0.68M

52-Week Price Return27.85%

EV / Free Cash Flow (Annual)284.79x

P/E Incl Extra (TTM)17.92x

Revenue / Employee (TTM)$1,021,228

Tangible BV / Share (Quarterly)$25.10

P/S Ratio (Annual)18.46x

Asset Turnover (Annual)0.55x

52-Week High$327.21

Operating Margin (5Y Avg)-1434.27%

EPS Excl Extra (Annual)$-4.36

CapEx CAGR (5Y)-17.01%

Tangible BV CAGR (5Y)7.07%

26-Week Price Return5.50%

Quick Ratio (Annual)0.72x

13-Week Price Return4.40%

Total Debt / Equity (Annual)1.93x

Current Ratio (Quarterly)2.99x

Enterprise Value$15.00B

Revenue / Share Growth (5Y)144.03%

Asset Turnover (TTM)0.62x

Book Value / Share Growth (5Y)-1.87%

Revenue / Employee (Annual)$702,428

Inventory Turnover (Annual)0.32x

Pretax Margin (Annual)-29.53%

Cash / Share (Annual)$11.53

3-Month Return Std Dev37.01%

Gross Margin (5Y Avg)77.81%

Net Income / Employee (TTM)$723,534

ROE (Last FY)-221.49%

Net Interest Coverage (Annual)0.26x

EPS Basic Excl Extra (Annual)$-4.36

P/FCF (TTM)37.93x

Receivables Turnover (TTM)6.61x

EV / Free Cash Flow (TTM)38.59x

Total Debt / Equity (Quarterly)0.31x

EPS Incl Extra (TTM)$12.79

Receivables Turnover (Annual)4.68x

ROI (TTM)51.13%

P/S Ratio (TTM)12.70x

Pretax Margin (5Y Avg)-1274.82%

Revenue / Share (Annual)$13.78

Tangible BV / Share (Annual)$5.31

Forward P/E18.61x

Price vs S&P 500 (52W)9.30%

P/E Ratio (TTM)17.92x

Year-to-Date Return16.26%

5-Day Price Return-1.60%

EPS Normalized (Annual)$-4.36

ROA (5Y Avg)-39.35%

Net Profit Margin (Annual)-31.67%

Month-to-Date Return1.64%

Cash Flow / Share (TTM)$-13.19

EBITD / Share (Annual)$-2.20

Operating Margin (Annual)-18.92%

LT Debt / Equity (Annual)1.83x

P/CF (TTM)38.04x

ROI (5Y Avg)-48.05%

P/E Excl Extra (TTM)17.92x

LT Debt / Equity (Quarterly)0.27x

EPS Basic Excl Extra (TTM)$12.79

P/TBV (Quarterly)10.64x

P/B Ratio (Annual)22.38x

Inventory Turnover (TTM)0.30x

Pretax Margin (TTM)9.34%

Book Value / Share (Annual)$5.34

Price vs S&P 500 (13W)2.44%

Beta0.33x

P/FCF (Annual)292.76x

Revenue / Share (TTM)$16.60

ROE (TTM)86.91%

52-Week Low$215.77

vGradeD

gGradeA

mGradeC

vgmGradeB

ASND Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	$0.89	$1.04	+17.39%(+$0.15)
Q1 2026	May 7, 2026	-$0.10	$0.31	+429.27%(+$0.41)

ASND Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.42

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	C	C	B	$17.54

About Ascendis Pharma A/S Ordinary Share

Ascendis Pharma is a biopharmaceutical company that develops therapeutics using its proprietary TransCon technology platform, with a pipeline focused on endocrinology and oncology indications including TransCon PTH and TransCon CNP. The company primarily generates revenue from the United States, with operations across Europe and international markets.